Who was studied, and how
Four numbers in the abstract
Where each one falls
Where it lands on the map
245people with type 2 diabetes, in this paper
Among treatment policy estimand, the trial randomly assignedassigned by chance
semaglutide 16 mg
semaglutide 2 mg
May have lowered weight change−3.40
No clear effect on HbA1c change−0.30
randomised · one subgroupAmong hypothetical estimand, the trial randomly assignedassigned by chance
semaglutide 16 mg
semaglutide 2 mg
May have lowered HbA1c change−0.50
May have lowered weight change−4.50
randomised · one subgroupthe abstract, start to end
… difference between 16 and 2 mg was -0.3 percentage points (%-points) (95% CI -0.7 to 0.2; P = 0.245) for HbA1c change and -3.4 kg (-6.0 to -0.8; P = 0.011) for weight change for the treatment policy estimand and -0.5%-points (-1.0 to -0.1; P = 0.015) and -4.5 kg (-7.6 to -1.4; P = 0.004), …
← favours treatmentfavours comparator →
could be chanceHbA1c changesemaglutide 16 mg vs semaglutide 2 mg, in treatment policy estimand
−0.3−0.70 to 0.20
Weight changesemaglutide 16 mg vs semaglutide 2 mg, in treatment policy estimand
−3.4−6.00 to −0.80
HbA1c changesemaglutide 16 mg vs semaglutide 2 mg, in hypothetical estimand
−0.5−1.00 to −0.10
Weight changesemaglutide 16 mg vs semaglutide 2 mg, in hypothetical estimand
−4.5−7.60 to −1.40
GLP-1 receptor agonistsGlycemic controlBody weight & composition
1 / 4